ARID1A and non-small cell lung carcinoma: Finally, additional experiments have shown that treatment of PDXs displaying MYC (focal amplification) and epigenetic (mutations of ARID1A and SMARCA4) alterations using a BET bromodomain inhibitor and an EZH2 inhibitor, respectively, did not induce antitumor effects in our NSCLC PDX models (Supplemental Figure S9).